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The balance and distribution of epithelial cell types is
required to maintain tissue homeostasis. A hallmark
of airway diseases is epithelial remodeling, leading
to increased goblet cell numbers and an overproduc-
tion of mucus. In the conducting airway, basal cells
act as progenitors for both secretory and ciliated
cells. To identify mechanisms regulating basal cell
fate, we developed a screenable 3D culture system
of airway epithelial morphogenesis. We performed a
high-throughput screen using a collection of sec-
reted proteins and identified inflammatory cytokines
that specifically biased basal cell differentiation to-
ward a goblet cell fate, culminating in enhanced
mucus production. We also demonstrate a specific
requirement for Notch2 in cytokine-induced goblet
cell metaplasia in vitro and in vivo. We conclude
that inhibition of Notch2 prevents goblet cell meta-
plasia induced by a broad range of stimuli and pro-
pose Notch2 neutralization as a therapeutic strategy
for preventing goblet cell metaplasia in airway
diseases.
INTRODUCTION
The lung epithelium has evolved to serve a number of functions,
ranging from gas exchange in the alveolus to the regulation of
mucus clearance in the larger conducting airways. The heteroge-
neous mix of epithelial cell types enables these functions at the
different levels of the airway. For example, mucin-producing
and secreting goblet cells provide a mucus gel that the multicili-
ated cells propel in a cephalad direction out of the airways,
whereas surfactant-producing type 2 pneumocytes maintain
alveolar patency with type 1 pneumocytes enabling gas ex-
change (Rackley and Stripp, 2012). A greater understanding ofCthe pathways that regulate the function of the epithelium as
well as those which define repair and remodeling in both health
and disease will be integral to our identification of therapeutic
targets to treat respiratory diseases such as severe asthma,
cystic fibrosis, and chronic obstructive pulmonary disease
(COPD).
A key feature common tomany airway diseases is epithelial re-
modeling, leading to an increase in the number of goblet cells
and an overproduction of mucus, called ‘‘goblet cell metaplasia’’
(gcm) (Fahy and Dickey, 2010). An inability to clear the increased
mucus can lead to airflow obstruction, mucostasis, and ulti-
mately death (Hogg et al., 2004; Kuyper et al., 2003; Lange
et al., 1998). Whereas an increase in several cytokines and
growth factors has been associated with airway diseases such
as asthma (Finkelman et al., 2010), only interleukin (IL)-13, and
the closely related cytokine IL-4, acting through a shared recep-
tor, have been shown to directly affect the airway epithelium to
increase goblet cell formation (Atherton et al., 2003; Dabbagh
et al., 1999; Gru¨nig et al., 1998; Kuperman et al., 2002; Laoukili
et al., 2001; Munitz et al., 2008). IL-13 is a key marker of the
‘‘Th2-high’’ asthma phenotype, which is seen in approximately
50% of patients with asthma (Woodruff et al., 2009). A recent
clinical trial with anti-IL-13 antibodies has demonstrated im-
proved airflow in patients with asthma, and this improvement
wasmore pronounced in patients with increased levels of perios-
tin, a downstream target of IL-13 (Corren et al., 2011). The factors
that drive gcm in asthmatics with a ‘‘Th2-low’’ phenotype, as well
as patients with COPD and cystic fibrosis (CF), are less well
defined.
In the present study, we describe the analysis of a method for
the 3D culture of primary human airway basal cells (broncho-
spheres). Developing bronchospheres respond to IL-13 with an
increase in the expression of markers of goblet cells and a
decline in ciliated cell number. We conducted a high-throughput
screen for secreted factors that influence bronchosphere devel-
opment and found a number of proteins that can bias basal cell
differentiation toward a goblet cell fate, thereby altering the
composition of the airway epithelium to produce the goblet cellell Reports 10, 239–252, January 13, 2015 ª2015 The Authors 239
Figure 1. Human Airway Basal Cells Form ‘‘Bronchospheres’’ in 3D Culture
(A) Human airway basal cells were grown overnight in chambered slides and stained for integrin a6 (ITGA6, green), p63 (orange), nerve growth factor receptor
(NGFR) (red), andDNA (blue). Note that all of the cells are positive for the airway basal cell markers ITGA6, p63, and NGFR. The DIC image is shown on the left, and
the overlay is on the right. The scale bar represents 10 mm.
(B) Phase contrast image of day 14 bronchospheres. The scale bar represents 100 mm.
(C) Quantitative PCR analysis of goblet (MUC5AC, MUC5B, and FOXA3), ciliated (FOXJ1 and DNAI2), and basal cell markers (p63 and ITGA6) expressed by
airway basal cells grown on plastic or after 14 days of growth in 3D into bronchospheres. Shown is the average ± SEM of at least four independent donors.
(D) Day 14 bronchospheres were fixed and stained for DNA (blue) and markers of basal cells (p63, red), ciliated cells (acetylated a-tubulin, orange), and goblet
cells (MUC5AC, green). The scale bar represents 50 mm.metaplasia described in many respiratory diseases. Finally, we
demonstrate that Notch2 is absolutely required for goblet cell
metaplasia in vitro and in vivo. We propose that Notch2 repre-
sents a novel therapeutic target for the prevention of goblet
cell metaplasia in human respiratory diseases such as asthma,
COPD, and CF.
RESULTS
Human Airway Basal Cells Form ‘‘Bronchospheres’’
in 3D Culture
Prior to plating primary human airway basal cells in Matrigel in
3D, we confirmed that they expressed the basal cell markers
p63, nerve growth factor receptor (NGFR), and ITGA6 (Figure 1A).
Immediately after seeding p63+NGFR+ITGA6+ basal cells in Ma-
trigel, the cells aggregated to form balls of cells that continued to
proliferate (Movie S1). Lumen formation initiated between days 8240 Cell Reports 10, 239–252, January 13, 2015 ª2015 The Authorsand 10 in 3D (Movie S2; Figure S1D), and by day 14, the majority
of structures contained a central lumen (Figure 1B). Immuno-
staining revealed p63+ cells basal to the cells lining the interior
of the cyst, consistent with a pseudostratified structure. In con-
trast, cells lining the central lumen were invariably negative for
Ki67 staining (data not shown). Ciliated cells, detected by acet-
ylated a-tubulin staining, were identified lining the central lumen
(Figure 1D). Furthermore, prior to fixation, the rapid beating of
these cilia could be observed under bright-field conditions
(Movies S3 and S4). In addition to ciliated cells, MUC5AC+ goblet
cells were also identified lining the central lumen (Figure 1D).
MUC5AC+ material was also seen inside of the central lumen
consistent with secretion of mucins by the epithelium in addition
to their storage (Figure 1D). A comparison of the expression of
cell-specific markers by quantitative PCR (qPCR) further high-
lighted the differentiation of the basal cells into a mucociliary
epithelium, with the appearance of markers of ciliated (FOXJ1
and DNAI2) and goblet cells (MUC5AC, MUC5B, and FOXA3;
Figures 1C and S1A–S1C).
With the knowledge that bronchospheres were composed of
at least three cell types, basal, ciliated, and goblet, we asked
whether this heterogeneity was a consequence of mixed popu-
lations of precommitted basal cells forming a bronchosphere
or whether the basal cells were indeed multipotent, as has
been described in themurine trachea (Rock et al., 2009). A clonal
seeding threshold was established to be%75 cells/well of a 384-
well plate using a labeled cell-mixing approach (Figure S1E). At
this seeding density, bronchospheres formed with an approxi-
mately 40% clonal efficiency. Bronchospheres were observed
to be composed of basal, goblet, and ciliated cells, confirming
the multipotent nature of p63+NGFR+ITGA6+ basal cells (Fig-
ure S1F). This provides an example of a 3D system that contains
the human conducting airway progenitor, the airway basal cell,
as well as the twomajor differentiated cell types that it generates,
goblet and ciliated cells, recapitulating the cellular complexity of
the conducting airway.
IL-13 Induces a Mucus Hypersecretory Phenotype in
Bronchospheres
We next asked whether bronchospheres could respond to
established inducers of airway epithelial remodeling. IL-13 has
been shown to be a key mediator of asthmatic phenotypes
(Wills-Karp, 2004), and several groups have demonstrated that
IL-13 acts directly on the epithelium to drive a goblet cell meta-
plasia phenotype (Atherton et al., 2003; Kuperman et al., 2002;
Laoukili et al., 2001). Treatment of developing bronchospheres
with IL-13, between days 2 and 14 after seeding, resulted in an
increase in the expression of markers of goblet cells, whereas
ciliated cell marker expression declined (Figure S2A). The induc-
tion of the remodeled phenotype was concentration dependent,
with the highest concentrations impairing differentiation, consis-
tent with previous observations using air-liquid interface (ALI) hu-
man bronchial epithelial (HBE) cultures (Atherton et al., 2003).
The enhanced expression of goblet cell markers was difficult
to observe and quantify by immunofluorescence in broncho-
spheres, largely due to the accumulation of secreted mucins in
the central lumen during culture. However, the loss of ciliated
cell marker expression was confirmed by a lack of acetylated
a-tubulin-positive structures in the IL-13-treated broncho-
spheres (Figures S2B and S2C).
Inflammatory Cytokines Alter Basal Cell Fates
Several inflammatory cytokines and growth factors have been
reported to increase the expression of MUC5AC in airway
epithelial cells (Chen et al., 2003; Fujisawa et al., 2009; Gray
et al., 2004; Kim et al., 2002). However, only IL-13, and the
closely related cytokine IL-4, acting through a shared receptor,
have been shown to act directly on the epithelium to drive a
goblet cell metaplasia phenotype, resulting in increased
numbers of goblet cells and fewer ciliated cells (Atherton et al.,
2003; Dabbagh et al., 1999; Gru¨nig et al., 1998; Kuperman
et al., 2002; Laoukili et al., 2001; Munitz et al., 2008). Goblet
cell metaplasia is a hallmark of several airway diseases, including
asthma and COPD (Fahy and Dickey, 2010), andwhether soluble
factors other than IL-13 act directly on the epithelium to drive thisCphenotype is not known. To identify novel factors that regulate
airway basal cell fate leading to a goblet cell metaplasia pheno-
type, we screened a collection of 4,876 secreted, recombinant
human proteins, representing 2,366 unique gene products
(Gonzalez et al., 2010) in the bronchosphere assay using cell-
type-specific expression markers as endpoints (Figure 2A).
Approximately 9% of the recombinant proteins (420/4,876), rep-
resenting 328 unique gene products, modulated expression of
one or more of the cell-type-specific markers by 2-fold or greater
(Table S1). The 420 recombinant proteins that affected the assay
could be classified into three groups: (1) one or more cell-type-
specific markers decreased by 2-fold or greater without a
concomitant increase in another marker (323/420); (2) one or
more markers of a particular cell type increased by 2-fold or
greater without a concomitant decrease of another marker (27/
420); and (3) one or more markers of one cell type increased
by 2-fold or greater with a concomitant decrease in markers of
one or two cell types (70/420; Table S1; Figure 2B).
The effect of the third group of proteins could be further
divided into two types of alterations in basal-cell-fate decision.
The first was treatments that resulted in an increase in a basal
cell marker and a decrease in one or more markers of ciliated
cells and/or goblet cells, consistent with inhibition of differen-
tiation. Interestingly, these proteins were almost exclusively
members of the epidermal growth factor (EGF) family of ligands
(14/15; Figure 2B). The second type of effect was an increase
in one or more of the goblet cell markers and a decrease in
one ormore ciliated or basal cell markers. More than half of these
proteins were inflammatory cytokines (33/54), suggesting that,
similar to IL-13, many inflammatory cytokines can bias the differ-
entiation of basal cells away from a ciliated cell fate and toward a
goblet cell.
IL-17A Treatment Biases Basal Cell Differentiation
toward a Goblet Cell
IL-17A is a cytokine that is secreted by Th17 cells and has been
proposed to play a role in severe asthma (Chesne´ et al., 2014).
IL-17A has been shown to stimulate mucin gene expression in
cultured airway epithelial cells (Chen et al., 2003) and enhance
airway smooth muscle contraction in vivo (Kudo et al., 2012).
Whether IL-17A can act directly on airway epithelial cells to alter
the composition of the epithelium and result in goblet cell meta-
plasia is not known. The results from our screen (Figure 2B) and
subsequent validation using a broader range of IL-17A concen-
trations (Figures 3A–3C) indicated that, in addition to increasing
MUC5AC levels, IL-17A treatment resulted in increased levels of
multiple markers of goblet cells (MUC5B and FOXA3), while in-
hibiting the expression of markers of ciliated cells (FOXJ1 and
DNAI2). These results suggest that IL-17A treatment can bias
the differentiation of the airway basal cell toward a goblet cell
at the expense of a ciliated cell, a phenotype similar to the goblet
cell metaplasia seen in many airway diseases.
To test this hypothesis, we utilized ALI cultures, seeding
airway basal cells onto transwell filters, treating the cultures
with IL-17A from day 7 (day 0 at ALI), prior to the initiation of
differentiation, and analyzing the resulting phenotype at day 21
(day 14 at ALI). Whereas cultures grown under control condi-
tions contained a mixture of goblet and ciliated cells at day 21,ell Reports 10, 239–252, January 13, 2015 ª2015 The Authors 241
Figure 2. A Screen of the Mammalian ‘‘Secretome’’ Identifies
Multiple Mediators of Goblet Cell Metaplasia In Vitro
(A) Molecular signature assay to monitor the relative abundance of goblet,
ciliated, and basal cells in vitro. Each data point is the median signal from an
individual well of a 384-well plate. Note that IL-13 treatment results in an in-
crease in the expression of goblet cell markers and a decrease in the
expression of ciliated cell markers, without affecting basal cell markers.
242 Cell Reports 10, 239–252, January 13, 2015 ª2015 The AuthorsIL-17A-treated cultures had a profound expansion of the goblet
cell population, together with a dramatic reduction in the number
of ciliated cells (Figures 3D and 3E). Together, our data indicate
that IL-17A is sufficient to bias basal cell fate toward a goblet cell
and away from a ciliated cell, resulting in a phenotype that is
similar to the goblet cell metaplasia seen in many airway
diseases.
Notch2 Is Required for Cytokine-Driven Effects on Basal
Cell Fate Specification In Vitro
The Notch-signaling pathway plays a key role in the determina-
tion of cell fate in multiple tissues throughout development (For-
tini, 2009). To determine the role of Notch in human airway basal
cell fate, we first analyzed the expression of Notch receptors
in (1) basal cells prior to plating in Matrigel, (2) fully formed
(day 14) bronchospheres, and (3) fluorescence-activated-cell-
sorting-purified ITGA6+ basal and ITGA6 luminal cells from
day 21 ALI cultures (Figure S3). qPCR analysis of genes that
are specifically expressed in basal cells (p63 and ITGA6), goblet
cells (MUC5AC,MUC5B, and FOXA3), and ciliated cells (FOXJ1
and DNAI2) confirmed that the ITGA6+ and ITGA6 populations
were enriched for basal cells and differentiated cells, respec-
tively (Figure S3). We found that airway basal cells, either prior
to plating in Matrigel or purified from day 21 ALI cultures as
well as bronchospheres and luminal cells from day 21 ALI
cultures, express Notch1, Notch2, and Notch3, but not Notch4
(Figure S3). To determine which of the Notch receptors is
required for human airway goblet cell formation, we treated
developing 3D bronchosphere cultures with Notch1-, Notch2-,
or Notch3-receptor-specific blocking antibodies (Li et al.,
2008; Wu et al., 2010). We first verified the selectivity of each
antibody using Notch-receptor-specific reporter gene assays
(Figure S4) and that each antibody inhibited the expression of
one or more endogenous Notch target genes in 3D broncho-
spheres (Bray and Bernard, 2010; Figure S4). All three antibodies
inhibited expression of the Notch target gene NRARP (Lamar
et al., 2001), whereas anti-Notch2 antibodies also inhibited
expression of HEY1 and HES5. Anti-Notch3 antibodies also in-
hibited HES5 expression, albeit to a lesser degree than anti-N2.
EachNotch-receptor-specific antibody had a distinct effect on
3D bronchospheres (Figures 4A–4C). Anti-Notch1 treatment led
to increased levels of multiple markers of basal cells (p63 and
ITGA6), without affecting the expression of goblet or ciliated
cell markers. Anti-Notch2 antibodies strongly inhibited the
expression of all three goblet cell markers (MUC5AC, MUC5B,
and FOXA3), while simultaneously increasing expression of
multiple ciliated cell markers (FOXJ1 and DNAI2) and one of
the two basal cell markers examined (p63), although to a lesser(B) Primary screen results from human airway basal cells grown in 3D in the
presence of the indicated proteins and analyzed for expression levels of the
indicated goblet, ciliated, and basal cell markers. Shown is a heatmap of
treatments that induced an increase of one or moremarkers of one cell type by
2-fold or greater, with a concomitant decrease in markers of one or both of the
other cell types by 2-fold or greater. Each data point is the signal intensity
relative to the median signal of the plate. Note that the treatments induce an
increase in a basal cell marker while decreasing goblet and/or ciliated markers
or an increase in one or both goblet cell markers while decreasing ciliated and/
or basal cell markers.
degree than anti-Notch1. Anti-Notch3 antibodies had a modest
inhibitory effect on two of the three goblet cell markers
(MUC5B and FOXA3), while slightly increasing the expression
of the basal cell marker ITGA6 at higher concentrations, without
affecting the expression of ciliated cell markers. Together, these
data indicate that Notch2, and not Notch1 or Notch3, is required
for the basal-cell-fate decision to become a goblet versus a cili-
ated cell.
We next asked whether blocking Notch2 or Notch3 could pre-
vent goblet cell metaplasia, a hallmark of several airway diseases
including asthma, CF, and COPD. Notch2 antibodies inhibited
IL-13-driven goblet cell metaplasia in vitro, as measured by
cell-type-specific gene expression in 3D bronchospheres (Fig-
ure 4D) and immunostaining with cell-type-specific markers in
ALI cultures (Figure 4G), whereas Notch3 inhibition had no effect
(Figure S5). Moreover, blocking Notch2, but not Notch3, partially
restored ciliated cells (Figures 4E, 4G, and S5) without affecting
basal cells (Figures 4F and S5), indicating that the effect of IL-13
on basal cell fate requires Notch2 activity. Interestingly, IL-13
treatment had no effect on the expression of the Notch target
gene NRARP (Figure S5), suggesting that Notch signaling is
not increased downstream of IL-13 and that Notch2 plays a
permissive, rather than an instructive role, in cytokine-driven
goblet cell metaplasia. We also found that Notch2 antibodies
at least partially inhibited the alteration in basal-cell-fate decision
downstream of a variety of inflammatory cytokines that we iden-
tified as driving goblet cell formation in our secretomics screen
(Figure 2B), as measured by qPCR for cell-type-specific markers
in bronchospheres (Figure 5) and immunostaining formucins and
acetylated alpha-tubulin in ALI cultures (Figure S6), indicating
that Notch2 signaling is generally required for goblet cell
metaplasia.
Inhibition of Notch2 Prevents Goblet Cell
Metaplasia In Vivo
To examine the effect of Notch2 inhibition on goblet cell meta-
plasia in vivo, we administered IL-13 intranasally into mice,
which induced a goblet cell phenotype (Figures 6B and 6C), as
previously reported (Wills-Karp et al., 1998), with or without
coadministration of anti-Notch2 antibodies. Expression levels
of the Notch target gene Nrarp were not modulated in animals
treated with IL-13 and were significantly reduced in animals
treated with the anti-Notch2 antibody, as measured by quantita-
tive RT-PCR analysis of RNA from whole-lung tissue (Figure 6F),
indicating that IL-13 does not directly activate Notch signaling
and verifying the inhibitory activity of anti-Notch2 antibodies
in vivo. Periodic acid-Schiff (PAS) staining of lung sections
revealed that coadministration of anti-Notch2 antibodies com-
pletely blocked IL-13-driven goblet cell metaplasia (Figures 6B
and 6C). In addition, the number of Foxj1+-ciliated cells was
dramatically increased in animals treated with the anti-Notch2
antibody (Figures 6D and 6E). We verified these observations us-
ing quantitative RT-PCR analysis of RNA from whole-lung tissue
(Figures 6G–6I). We found that coadministration of anti-Notch2
antibodies together with IL-13 suppressed the expression
of multiple goblet-cell-specific genes (Muc5ac, Muc5b, and
Foxa3), while dramatically increasing the levels of multiple cili-
ated-cell-specific genes (Foxj1 and Dnai2), relative to animalsCtreated with IL-13 alone. Anti-Notch2 antibody administration
also had a slight but significant increase in the basal-cell-specific
genes Trp63 and Itga6. Together, these data indicate that
Notch2 is required for IL-13-driven goblet cell metaplasia
in vitro and in vivo.
We next examined the effects of anti-Notch2 administration in
a model of allergic asthma, where mice are chronically exposed
to house dust mite (HDM) to induce many of the clinical symp-
toms seen in humans, including goblet cell metaplasia (Johnson
et al., 2004). Similar to the effects seen on IL-13-induced goblet
cell metaplasia, anti-Notch2 antibodies profoundly reduced the
amount of mucus induced by HDM administration, as measured
by the relative area of PAS staining (Figures S7A and S7B), while
dramatically increasing the number of Foxj1+-ciliated cells (Fig-
ures S7C and S7D).
Finally, we examined whether anti-Notch2 administration
could revert an established goblet cell metaplasia phenotype.
The experimental design is schematically depicted in Figure 7A.
We induced a goblet cell metaplasia phenotype by intranasal
administration of IL-13 for 3 days prior to initiating anti-Notch2
antibody treatments. IL-13 administration, with or without
anti-Notch2 antibody, was continued for an additional 6 days.
The animals were then analyzed 1 day after the final treatment.
Reduced expression of the Notch target gene Nrarp in the anti-
Notch2-antibody-treated animals, as measured by qPCR anal-
ysis of RNA from whole-lung tissue, confirmed Notch pathway
inhibition (Figure 7F). PAS staining of lung sections, to measure
mucus production (Figure 7B), and quantitative RT-PCR analysis
of the expression levels of the goblet-cell-specific genes Mu-
c5ac, Muc5b, and Foxa3 in RNA from whole-lung tissue (Fig-
ure 7G) confirmed that the goblet cell metaplasia phenotype
had occurred after 3 days of IL-13 administration and that this
phenotype was completely reversed after treatment with the
anti-Notch2 antibody (Figures 7B, 7C, and 7G).
DISCUSSION
Goblet cell metaplasia is a hallmark of several airway diseases,
such as asthma, CF, and COPD. The inability to clear the result-
ing increase in mucus production can ultimately result in muco-
stasis and death (Hogg et al., 2004; Kuyper et al., 2003; Lange
et al., 1998). Several secreted proteins have been demonstrated
to increase mucin expression or secretion in tracheal or airway
epithelial cells in culture (Adler et al., 1995; Chen et al., 2003; Fu-
jisawa et al., 2009; Gray et al., 2004; Kettle et al., 2010; Levine
et al., 1995; Vermeer et al., 2003); however, only IL-13 and the
closely related cytokine IL-4, acting through a shared receptor,
have been demonstrated to act directly on the airway epithelium
to increase the number of goblet cells in vitro and in vivo by
altering airway epithelial cell fate (Atherton et al., 2003; Dabbagh
et al., 1999; Gru¨nig et al., 1998; Kuperman et al., 2002; Laoukili
et al., 2001; Munitz et al., 2008).
In this study, we utilized a 3D culture model of airway epithelial
morphogenesis. 3D culture models utilizing cell lines derived
from several epithelial tissues, including kidney (MDCK), in-
testine (Caco-2), and mammary gland (MCF-10A), have been
previously described (Debnath et al., 2003; Elia and Lippincott-
Schwartz, 2009; Jaffe et al., 2008). Recently, Rock et al. (2009)ell Reports 10, 239–252, January 13, 2015 ª2015 The Authors 243
Figure 3. IL-17A Biases Basal Cell Fate toward a Goblet Cell and away from a Ciliated Cell
(A–C) Human airway basal cells were grown in 3D to produce bronchospheres, in the presence of increasing concentrations of IL-17A, and analyzed for
expression levels of the indicated goblet cell markers (A), ciliated cell markers (B), and basal cell markers (C). Shown is the mean fold change ± SEM relative to
control from three independent experiments (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. One-way ANOVA and Dunnett’s multiple comparison test.
(legend continued on next page)
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described the formation of ‘‘tracheospheres’’ from either Krt5+
murine basal cells or ITGA6+NGFR+ human basal cells in 3DMa-
trigel-based culture. Tracheospheres contained a central lumen
surrounded by ciliated cells but lacked detectable MUC5AC+
secretory cells (Rock et al., 2009). Wu et al. (2010) also reported
the formation of polarized 3D structures in Matrigel that were
derived from surface epithelial HBE cells (Wu et al., 2011). These
structures that were cultured on four chamber slides were
termed ‘‘glandular acinar’’ cells based upon the expression of
MUC5B and the lack of ciliated cells (Wu et al., 2011). Whereas
each of these systems recapitulates some aspects of the archi-
tecture of the conducting airway, neither captures the full diver-
sity of cell types found in this region of the respiratory tract. In
particular, there are no reported 3D culture systems that contain
an airway progenitor cell, mucus-producing secretory cells, and
ciliated cells. The bronchospheres described in this study derive
frommultipotent p63+NGFR+ITGA6+ airway basal cell, a progen-
itor cell for the human conducting epithelium, and recapitulate
key elements of the conducting airway epithelium, including a
pseudostratified epithelium containing basal cell progenitors,
mucus-secreting goblet cells, and ciliated cells, surrounding a
single central lumen.
We scaled the 3D bronchosphere system to a 384-well plate
format to allow for much higher throughput screening and ana-
lyses when compared with the widely used ALI cultures of pri-
mary epithelia (Gray et al., 1996). We used this system to screen
a library of secreted proteins (Gonzalez et al., 2010) and found a
number of factors that modulated basal cell fate, as judged by
a decrease in one or more cell-type-specific markers with a
concomitant increase in one or more markers of another cell
type. One group of treatments drove an increase in a basal cell
marker and a decrease in one or more markers of ciliated cells
and/or goblet cells, consistent with inhibition of differentiation.
Interestingly, these proteins were almost exclusively members
of the epidermal growth factor family of ligands. A recent study
found that EGF receptor is expressed by human airway basal
cells, and is activated by smoke-induced EGF expression in cili-
ated cells to prevent basal cell differentiation into ciliated and
goblet cells and drive a squamous metaplasia phenotype (Shay-
khiev et al., 2013). Our data suggest that other EGF ligands may
have a similar activity and could play a role in driving squamous
metaplasia in other settings.
The second type of effect that we observed on basal cell fate
was an increase in one or more of the goblet cell markers and a
decrease in one or more ciliated or basal cell markers. More than
half of the proteins that biased cell fate toward a goblet cell were
inflammatory cytokines. This has several implications for the
treatment of airway diseases. First, it provides a rationale for
the development of cytokine-specific therapies and stratifying(D) Human airway basal cells were grown on filters at air-liquid interface with or w
row) and IL-17A-treated (bottom row) filters stained for MUC5AC (orange), MUC
Quantification of the total staining area for each marker is shown to the right. Show
experiments, each performed in duplicate. *p < 0.01; **p < 0.001. Paired, two-ta
(E) Representative confocal sections of control (top) and IL-17A-treated (bottom) fi
and DNA (blue). The scale bar represents 10 mm. Quantification of the number
was performed with four independent regions of each filter from the experiment
IL-17A-treated filters, respectively. Shown is the percentage of cells stained for
Cpatients based on either levels of a particular cytokine or a
biomarker indicating activation of a pathway downstream of a
particular cytokine. The increased response in asthma patients
with higher levels of periostin in recent clinical trials with anti-
IL-13 antibodies supports this idea (Corren et al., 2011). Second,
it suggests that treatments designed to inhibit the production or
secretion of mucus from goblet cells may not be sufficient,
because they may not restore the appropriate numbers of cili-
ated cells required for adequate mucociliary clearance. Finally,
although the factors we found to influence basal cell fate activate
distinct signaling pathways, their similar effect on a cellular pro-
cess, biasing progenitor cell fate toward a goblet cell and away
from a ciliated cell, suggested that theremay be a common drug-
gable node that would have therapeutic benefit for patients with
a wide range of underlying causes.
Notch signaling is an evolutionarily conserved pathway that
regulates many cell-fate decisions during development (Fortini,
2009). Mammalian cells contain four Notch receptors (Notch 1–
Notch 4), which are activated by membrane-bound ligands,
members of the Delta and Jagged family, on neighboring cells.
Notch activation leads to a series of cleavage events, culmi-
nating in the generation of the Notch intracellular domain
(NICD), which translocates to the nucleus, where it interacts
with a transcription factor complex to regulate gene expression.
The role of Notch signaling in regulating cell-fate decisions dur-
ing development and repair has been studied in many contexts,
including in mucociliary tissues (Deblandre et al., 1999; Guseh
et al., 2009; Morimoto et al., 2010, 2012; Rock et al., 2011;
Tsao et al., 2009). In the epidermis of the Xenopus embryo, acti-
vation of Notch suppresses the ciliated cell fate, whereas inhibi-
tion of Notch signaling results in an overproduction of ciliated
cells (Deblandre et al., 1999). In the developing mouse airway,
expression of the NICD results in an overproduction of secretory
cells at the expense of ciliated cells (Guseh et al., 2009), whereas
deletion of Pofut1, an O-fucosyltransferase required for Notch-
ligand interactions (Stahl et al., 2008), or Rbpjk, a core nuclear
effector of Notch signaling (Fortini, 2009), results in an increase
in the number of ciliated cells and a near absence of secretory
cells (Tsao et al., 2009). A recent study using Notch-receptor-
specific knockouts suggested that Notch2 is the critical Notch
receptor regulating secretory versus ciliated cell fate in the
mouse developing airway (Morimoto et al., 2012).
We found that Notch2 acts as a common node downstream of
IL-13, as well as the mediators of goblet cell metaplasia identi-
fied in this study. Antibodies that specifically inhibit Notch2,
but not other Notch receptor family members Notch1 and
Notch3, inhibit IL-13-driven goblet cell metaplasia in vitro, and
administration of anti-Notch2 antibodies prevented IL-13 as
well as allergen-driven goblet cell metaplasia in vivo. Moreover,ithout IL-17A (10 ng/ml). Shown are representative tiled images of control (top
5B (green), and acetylated a-tubulin (red). The scale bar represents 500 mm.
n is the average fold change ± SEM relative to control from three independent
iled Student’s t test.
lters stained for MUC5AC (red), MUC5B (green), acetylated a-tubulin (orange),
of cells staining positive for each marker is shown to the right. Quantification
s shown in (D). A total of more than 700 cells were counted from control and
each marker.
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Figure 4. Notch2 Inhibition Alters Cell Fate away from a Goblet Cell and toward a Ciliated Cell
(A–C) Human airway basal cells were grown in 3D to produce bronchospheres, in the presence of vehicle control; IgG (10 mg/ml); or increasing concentrations
(mg/ml) of inhibitory antibodies specific for Notch1 (a-N1), Notch2 (a-N2), or Notch3 (a-N3), and analyzed for the expression levels of the indicated goblet cell
(legend continued on next page)
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Notch2 antibodies prevented the changes in basal cell fate
driven by multiple cytokines in our 3D bronchosphere system
and in ALI cultures, including cytokines that are increased in pa-
tients with asthma, COPD, or both, which have been proposed to
play a role in these diseases (Barnes, 2008). Finally, we found
that administration of anti-Notch2 antibodies reversed a pre-es-
tablished goblet cell metaplasia phenotype in vivo. Collectively,
our data support the use of Notch2-specific inhibitors in the
treatment of airway diseases with goblet cell metaplasia, regard-
less of the disease stimulus.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents
Primary antibodies used in this studywereMUC5AC (clone 45M1; Thermo Sci-
entific), acetylated a-tubulin (clone 6-11B-1; Sigma-Aldrich), mouse anti-p63
(clone 4A4; Santa Cruz Biotechnology), rabbit anti-p63 (Abcam), ITGA6 (Go
H3; Abcam), NGFR (Abcam), Ki-67 (Invitrogen), and FOXJ1 (HPA005714;
Sigma). Alexa 488, Alexa Fluor 568, and Alexa Fluor 633 secondary antibodies,
Alexa Fluor 647 and rhodamine-conjugated phalloidin, Oregon Green 488 car-
boxylic acid diacetate (carboxy-DFFDA), and ProLong gold antifade with DAPI
were obtained from Invitrogen.
Tissue Culture
Human airway basal cells (sold as ‘‘normal human bronchial/tracheal epithe-
lial cells’’) and culture media were obtained from Lonza. All cells purchased
from Lonza were from normal donors, ranging in age from 3 to 60 years old.
Air-liquid interface cultures using passage 2 (P2) cells were performed as
previously described (Danahay et al., 2002). At this passage, these cells
retain the ability to differentiate into a mucociliary epithelium at ALI, whereas
at higher passages (>4), the cells lose this ability (Araya et al., 2007; Gray
et al., 1996). For 3D culturing of airway basal cells, P1 cells were trypsinized
and resuspended (30,000 cells/ml) in HBE differentiation media containing
5%-growth-factor-reduced Matrigel (BD Biosciences). Twenty microliters
of suspension was plated in each well of a 384-well plate (Greiner) precoated
with 10 ml of a 25% solution of Matrigel (BD Biosciences) in HBE differenti-
ation media. Wells were fed or treated at day 2 and day 8 of culture by add-
ing 30 ml of differentiation media containing the appropriate treatment.
3D cultures were analyzed at the time points indicated. For the cell-mixing
experiments to determine the seeding density for deriving clonal broncho-
spheres, airway basal cells were labeled with carboxy-DFFDA and mixed
with unlabeled HBE cells at a 1:1 ratio prior to plating in 3D in 384-well
plates.
For screening studies of 3D bronchosphere cultures, P1 cells and 384-well
plates were prepared and treated in duplicate with a collection of 4,876
secreted, recombinant human proteins representing the predicted human ‘‘se-
cretome’’ (Gonzalez et al., 2010), essentially as described above. To automate
the process, a Wellmate (Thermo Scientific) microplate dispenser was used to
plate cells and a Biomek FXP 384-multichannel pipetting head (Beckman
Coulter) was used to precoat, feed, and treat wells. Protein and control sam-
ples suspended in Tris-buffered saline buffer were arrayed in 384-well v-bot-
tom plates (Greiner). Samples were diluted to a working concentration in assaymarkers (A), ciliated cell markers (B), and basal cell markers (C). Shown is the
experiments. *p < 0.05; **p < 0.01; ***p < 0.001. One-way ANOVA and Dunnett’s
(D–F) Human airway basal cells were grown in 3D to produce bronchospheres, in t
increasing concentrations of a-N2 (mg/ml) together with 1 ng/ml of IL-13, and ana
cell markers (E), and basal cell markers (F). Shown is the mean fold change ± SEM
0.01; ***p < 0.001. One-way ANOVA and Dunnett’s multiple comparison test.
(G) Representative tiled images of ALI cultures treated with IgG control (first colum
IL-13 + a-N2 (fourth column) and stained forMUC5AC (green), MUC5B (red), and a
the total staining area for each marker is on the right. Shown is the average fold ch
five filters per treatment. Note that a-N2 inhibits the IL-13-driven increase in MUC5
0.001. Paired, two-tailed Student’s t test.
Cmedia with 0.1% BSA (Sigma) and were then used to treat wells at day 2 and
day 8 of culture at a final concentration of 4.4 nM–1.24 mM (indicated in Table
S1), depending on the sample protein. To record 3D structure morphology, a
bright-field image of each well was taken on day 12 of culture using an IN
Cell Analyzer 2000 high-content imaging system (GE Healthcare Life Sci-
ences). Gene expression was quantified on day 14 of culture using the Quan-
tiGene Plex 2.0 Assay (Affymetrix).
QuantiGene 2.0 Multiplex Assays
To quantify gene expression of 3D bronchosphere cultures, the QuantiGene
2.0 Multiplex Assay (Affymetrix) was used. All sample transfers were done
with a Biomek FXP 384-multichannel pipetting head (Beckman Coulter). Solu-
tion additionswere donewith aWellmatemicroplate dispenser (Thermo Scien-
tific). Wells were aspirated and washed with an ELX406 plate washer (BioTek).
RNA was processed with the QuantiGene Sample Processing kit (Affymetrix)
according to the manufacturer’s specifications. Briefly, day 14 bronchosphere
plates (384-well) were aspirated to 30 ml and 15 ml of Panomics Lysis mixture
was added. A 40 ml sample of each well was transferred to a 384-well v-bottom
plate (Greiner), and 20 ml of a hybridization solution containing lysis mixture,
proteinase k, blocking reagent, a probe set, and a bead set was added to
each well. To hybridize RNA, probes, and beads, plates were sealed and incu-
bated at 55C overnight in an orbital shaking incubator at 500 rpm (Liconic).
The probe set containing the following target genes: POLR2A (NM_000937);
ITGA6 (NM_001079818); MUC5B (NM_002458); MUC5AC (NM_017511);
p63 (NM_003722); DNAI2 (NM_023036); and FOXJ1 (NM_001454) is available
from Affymetrix (panel 11783/catalog no. 311783). The next day, wash
solution, preamplifier solution, amplifier solution, and label probe streptavi-
din-phycoerythrin (SAPE) solution were prepared using the manufacturer’s
specifications. Hybridized RNA was multiplexed by combining in a clear,
flat-bottom, 384-well plate (Nunc). The plate was placed on amagnetic holder,
and wells were washed three times. RNA was incubated for 1 hr at 50C and
500 rpm with preamplifier solution and then washed as before. This incubation
and wash cycle was repeated for addition of amplifier solution and again for
label probe SAPE solution. A bead-suspending solution was added, and
each well was then read using the Flexmap 3D instrument (Luminex). RNA
quality was monitored by examining the signal for a housekeeper (POLR2A)
to ensure that the levels were similar to other wells. The effect of each of the
recombinant proteins screened was determined by calculating the average
(n = 2 replicates for the screen) of the median signal of a well relative to the me-
dian signal of the plate (excluding active control wells) for each probe (i.e., for
each target gene).
Microscopy
Immunofluorescence of 3D bronchospheres was performed as described
previously for MCF10A cysts (Debnath et al., 2003) with the following modifi-
cations. After incubation with fluorescence-conjugated secondary antibodies,
DNA was stained with a 1:1 mix of PBS and ProLong gold antifade containing
DAPI. Confocal microscopy was performed at room temperature on a micro-
scope (Zeiss LSM510 Meta) using an EC Plan-Neofluar 103/0.30 dry objec-
tive (Zeiss), an EC Plan-Neofluor 203/0.5 dry objective (Zeiss), a C-Apochro-
mat 403/1.2 W corr (Zeiss), or a C-Apochromat 633/1.2 W Corr objective
(Zeiss). Images were collected with Zen confocal software (Zeiss). Scale
bars were added, and images were processed using Zen (Zeiss) and Photo-
shop (Adobe). ALI cultures were processed for immunofluorescence analysismean fold change ± SEM relative to control from at least three independent
multiple comparison test.
he presence of vehicle control or IgG (10 mg/ml), with or without 1 ng/ml IL-13, or
lyzed for the expression levels of the indicated goblet cell markers (D), ciliated
relative to control from at least four independent experiments. *p < 0.05; **p <
n), a-N2 (second column), 1 ng/ml IL-13 + IgG control (third column), or 1 ng/ml
cetylated a-tubulin (orange). The scale bar represents 500 mm.Quantification of
ange ± SEM relative to control from three independent experiments, each with
AC staining and partially restores levels of acetylated a-tubulin. *p < 0.01; **p <
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Figure 5. Notch2 Inhibition Blocks Goblet Cell Metaplasia Downstream of Multiple Mediators
Human airway basal cells were grown in 3D to produce bronchospheres, in the presence of IgG (0.1 mg/ml) or a-N2 (0.1 mg/ml), together with the indicated
proteins, and analyzed for the expression levels of goblet cell markers (A), ciliated cell markers (B), and basal cell markers (C). Shown is the mean fold change ±
SEM relative to control from at least three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant. Paired, two-tailed Student’s t test.after 14 days of culture at ALI by rinsing the apical surface of each filter with
PBS and then fixing in 4% paraformaldehyde for 4 hr. Filters were washed
with IF buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 7.7 mM
NaN3, 0.1% bovine serum albumin, 0.2% Triton X-100, and 0.05% Tween-
20), blocked with IF wash containing 10% goat serum, and stained with
primary antibody in IF wash containing 10% goat serum overnight at 4C.
Secondary antibodies were used at a 1:200 dilution in IF buffer containing248 Cell Reports 10, 239–252, January 13, 2015 ª2015 The Authors10% goat serum. To quantify the total staining area of ALI cultures, 10 3
13 images were collected with a plan Neofluar 103 0.3 numerical aperture
(NA) Ph1 objective (EC; Carl Zeiss) on a microscope (Axiovert 200; Carl Zeiss)
equipped with a motorized stage and a camera (Orca-ER-1394; Hamamatsu
Photonics) controlled by Axiovision software (Carl Zeiss) and used to
generate a single composite image using the MOSAIX function in Zeiss Axio-
vision. Quantification of the total staining area was performed with ImageJ.
Figure 6. Notch2 Neutralization Inhibits IL-13-Driven Goblet Cell Metaplasia In Vivo
(A) Schematic representation of the experimental design.
(B) Representative images of PAS-stained lung sections from the indicated treatment groups (8–10 mice per group). PAS positivity is dark violet. The scale bar
represents 200 mm. The inset scale bar represents 20 mm.
(C) Quantification of the relative area of PAS staining in the lung. Shown is the mean ± SEM. Each dot represents one mouse.
(D) Representative images of lung sections from the indicated treatment groups (8–10 mice per group) stained for the ciliated-cell-specific marker Foxj1. The
scale bar represents 200 mm. The inset scale bar represents 20 mm.
(E) Quantification of the number of Foxj1+ cells per 100 mm of epithelium. Shown is the mean ± SEM. Each dot represents one mouse.
(F) Quantitative PCR analysis of the Notch target gene Nrarp in lungs from the indicated treatment groups.
(G–I) Quantitative PCR analysis of goblet (Muc5ac,Muc5b, and Foxa3; G), ciliated (Foxj1 and Dnaic2; H), and basal cell marker (Trp63 and Itga6; I) expression in
lungs from the indicated treatment groups. Shown is the mean fold change ± SEM relative to control. Each dot represents one mouse. *p < 0.05; **p < 0.01; ***p <
0.001. One-way ANOVA and Dunnett’s multiple comparison test.Two to three regions of each ALI culture were punched out with a 4 mm bi-
opsy punch (Miltex) and mounted in ProLong gold antifade containing DAPI
for imaging by confocal microscopy on a microscope (Axiovert 200; Carl
Zeiss) equipped with a motorized stage, a Yokogawa CSU-X1 spinning disc
head, and an electron-multiplying charge-coupled device camera (Evolve
512; Photometrics), with a Plan-Apochromat 1003/1.4 oil differential interfer-
ence contrast (DIC) objective (Zeiss). Cells positive for MUC5AC, MUC5B, or
cilia (acetylated a-tubulin) staining were counted manually. For time-lapse
video microscopy, human bronchial epithelial cells were imaged at the indi-
cated times during bronchosphere development at 37C with a plan Neofluar
103 0.3 NA Ph1 objective (EC; Carl Zeiss). Images were taken every 5 min forCthe indicated time period. Annotations (time stamp and scale bar) were
added, and videos were assembled using Axiovision software.
RNA Isolation and Quantitative PCR
RNA was isolated from 3D bronchosphere cultures with Trizol (Invitrogen), us-
ing manufacturer’s specifications. To isolate RNA from mouse tissue, approx-
imately 20 mg of tissue was placed in a 1.5 ml Eppendorf tube with 1 ml of
Buffer RLT Plus (QIAGEN) containing 10 ml of 2-mercaptoethanol (Sigma). A
5 mm stainless steel bead (QIAGEN) was added to the tube, and the tissue
was sheared using a Tissue Lyser II (QIAGEN). RNA from the sheared tissue
was purified using the RNeasy Plus Mini Kit (QIAGEN), using manufacturer’sell Reports 10, 239–252, January 13, 2015 ª2015 The Authors 249
Figure 7. Notch2 Neutralization Reverts a Preexisting IL-13-Induced Goblet Cell Metaplasia In Vivo
(A) Schematic representation of the experimental design.
(B) Representative images of PAS-stained lung sections from the indicated treatment groups (8–10 mice per group). PAS positivity is dark violet. The scale bar
represents 100 mm. The inset scale bar represents 10 mm.
(C) Quantification of the relative area of PAS staining in the lung. Shown is the mean ± SEM. Each dot represents one mouse.
(D) Representative images of lung sections from the indicated treatment groups (8–10 mice per group) stained for the ciliated-cell-specific marker Foxj1. The
scale bar represents 100 mm. The inset scale bar represents 10 mm.
(E) Quantification of the number of Foxj1+ cells per 100 mm of epithelium. Shown is the mean ± SEM. Each dot represents one mouse.
(F–H) Quantitative PCR analysis of goblet (Muc5ac,Muc5b, and Foxa3; F), ciliated (Foxj1 and Dnaic2; G), and basal cell marker (Trp63 and Itga6; H) expression in
lungs from the indicated treatment groups.
(I) Quantitative PCR analysis of the Notch target gene Nrarp in lungs from the indicated treatment groups. Shown is the mean fold change ± SEM relative to
control. Each dot represents one mouse. *p < 0.05; ***p < 0.001; ns, not significant. One-way ANOVA and Dunnett’s multiple comparison test.specifications. TaqManReverse TranscriptionReagents (Invitrogen)were used
to generate cDNA from1 mg of total RNA.Quantitative PCRwas performedon a
ViiA7 Real-Time PCR System (Applied Biosystems), using 40 ng of cDNA per
reaction with the following Taqman probes (Applied Biosystems): MUC5AC,
Hs01365601_m1; MUC5B, Hs00861588_m1; FOXA3, Hs00270130_m1;
FOXJ1, Hs00230964_m1; DNAI2, Hs01001544_m1; p63, Hs00978340_m1;
ITGA6, Hs01041011_m1; NOTCH1, Hs01062011_m1; NOTCH2, Hs010
50702_m1; NOTCH3, Hs01128541_m1; NOTCH4, Hs00965897_m1; HEY1,
Hs01114113_m1; HEY2, Hs00232622_m1; HES1, Hs00172878_m1; HES5,
Hs01387463_g1; NRARP, Hs01104102_s1; GAPDH, Hs99999905_m1; Mu
c5ac, Mm012718_m1; Foxj1, Mm012367279_m1; Trp63, Mm00495788_m1;
and Gapdh, Mm99999915_g1.250 Cell Reports 10, 239–252, January 13, 2015 ª2015 The AuthorsAnimal Models
Female Balb/c mice (20–25 g) were obtained from Charles River Lab-
oratories. Mice were housed under specific pathogen-free conditions
and were provided with food and water ad libitum. Experiments were
performed in accordance with the UK Animals Scientific Procedures Act
1986.
For the experiment shown in Figure 6, mice received 0.5 mg of recombinant
mouse IL-13 (Ebiosciences) or PBS intranasally on 3 consecutive days (days
1–3). Mice received either 20 mg/kg neutralizing antibody to Notch2 or control
immunoglobulin G (IgG) or PBS intraperitoneally 2 hr before intranasal chal-
lenge with either IL-13 or PBS on days 1 and 3 only. Mice were euthanized
24 hr after the final IL-13 administration.
For the experiment shown in Figure S7 (chronic house dust mite model),
mice received 25 mg of HDM (D. pteronyssinus; GREER Laboratories) or saline
intranasally on 5 days a week for 5 weeks (days 1–5, 8–12, 15–19, 22–26, and
29–31). Mice received either 20 mg/kg neutralizing anti-Notch2 antibody or
isotype control IgG intraperitoneally 2 hr before intranasal challenge with
HDMon days 22, 24, 26, 28, and 30 only. Mice were euthanized 24 hr after their
final saline or HDM administration (day 32).
For the experiment shown in Figure 7, mice received 0.5 mg of recombinant
mouse IL-13 (Ebiosciences) or PBS intranasally on 10 consecutive days (days
1–10). Mice received either 20 mg/kg neutralizing anti-Notch2 antibody or
isotype control IgG intraperitoneally 2 hr before intranasal challenge with either
IL-13 or PBS on days 4, 6, 8, and 10 only. An additional group of mice received
0.5 mg of recombinant mouse IL-13 (Ebiosciences) or PBS intranasally on 3
consecutive days (days 1–3) only. Mice were euthanized 24 hr after their final
PBS or IL-13 administration.
The left lungs were excised, inflated with 10% neutral buffered formalin
(NBF), and preserved in NBF. Lungs were embedded in paraffin wax and
lung sections obtained for each animal. Sections were stained with PAS
stain for mucus and with anti-Foxj1 antibodies (Sigma) to label ciliated
cells.
PAS-positive staining and Foxj1-positive nuclei were quantified in lung
sections using Definiens Image Analysis software. Two distinct lung
sections were analyzed per mouse, and the total area of PAS-positive
staining or the number of Foxj1-positive nuclei within the sections was
determined. The PAS-positive staining was normalized to the area of tissue
analyzed and represented as ‘‘relative area PAS-positive mucus (%)’’. The
Foxj1-positive nuclei are represented as ‘‘Foxj1+ cells per 100 mm’’ of
epithelium.
Data are expressed asmean ±SEM. Statistical significancewas determined
using a parametric one-way ANOVA and Dunnett’s posttest. GraphPad Prism
(version 5.04) was used to generate graphs and perform statistical analysis.
***p < 0.001 denotes statistically significant difference from relevant isotype
control group.
Additional methods are provided in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, one table, and four movies and can be found with this article on-
line at http://dx.doi.org/10.1016/j.celrep.2014.12.017.
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